Shares of AstraZeneca plc (NYSE:AZN) have received an average rating of “Hold” from the twenty ratings firms that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $45.29.
Several equities research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. Main First Bank reissued a “buy” rating on shares of AstraZeneca in a research note on Tuesday, March 19th. Goldman Sachs Group reissued a “sell” rating on shares of AstraZeneca in a research note on Tuesday, February 26th. Deutsche Bank restated a “buy” rating on shares of AstraZeneca in a report on Tuesday, February 26th. Finally, HSBC restated a “sell” rating on shares of AstraZeneca in a report on Thursday, February 28th.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Golden State Wealth Management LLC bought a new position in shares of AstraZeneca in the first quarter worth about $28,000. Berman Capital Advisors LLC bought a new position in shares of AstraZeneca in the fourth quarter worth about $38,000. Pinnacle Bank bought a new position in shares of AstraZeneca in the fourth quarter worth about $38,000. Portfolio Solutions LLC bought a new position in shares of AstraZeneca in the fourth quarter worth about $40,000. Finally, Sontag Advisory LLC bought a new position in AstraZeneca during the 4th quarter worth about $40,000. Hedge funds and other institutional investors own 18.32% of the company’s stock.
AstraZeneca (NYSE:AZN) last announced its earnings results on Friday, April 26th. The company reported $0.45 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.02. AstraZeneca had a net margin of 10.75% and a return on equity of 37.91%. The business had revenue of $5.47 billion for the quarter, compared to the consensus estimate of $5.40 billion. During the same quarter in the prior year, the firm posted $0.48 earnings per share. The business’s revenue for the quarter was up 9.6% on a year-over-year basis. Analysts predict that AstraZeneca will post 1.79 earnings per share for the current fiscal year.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: How does a reverse stock split work?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.